After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...

Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Regionally, North America leads the Global Plasma Fractionation Market, accounting for approximately 54% of the total market share in 2026. The region's dominance is supported by well-established plas ...

Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...

BioArctic's AB (publ) (STOCKHOLM: BIOA B ) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Rani Therapeutics Holdings, Inc. ('Rani Therapeutics” or 'Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company ...

Avtozma is among the first wave of tocilizumab biosimilars with both intravenous and subcutaneous formulations approved and ...

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

INCHEON, South Korea, March 16, 2026 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) ...